A groundbreaking combination therapy has demonstrated significant benefits for patients with KRAS G12C metastatic colorectal cancer that no longer responds to chemotherapy, according to a Phase 3 clinical trial led by researchers at City of Hope. Published in the Journal of Clinical Oncology, the study reveals that the combination of sotorasib and panitumumab significantly extends progression-free survival, offering new hope for this hard-to-treat patient population.
The trial, named CodeBreaK 300, involved 160 patients with KRAS G12C-mutated colorectal cancer that had progressed despite standard treatments. Participants were divided into three groups: one received a high dose of sotorasib (960 mg) with panitumumab, another received a lower dose (240 mg) with panitumumab, and the third received standard care drugs (trifluridine/tipiracil or regorafenib).
Results showed that over 30% of patients in the high-dose group achieved a significant reduction in tumor volume, compared to just 1.9% in the standard care group. Additionally, progression-free survival was notably longer in the high-dose group, and early data suggested a 30% improvement in overall survival, though further studies are needed to confirm this finding.
Dr. Marwan Fakih, the study’s senior author, emphasized the potential of this combination as a new standard of care. “This treatment prolongs disease control and offers a much-needed option for patients who have exhausted other therapies,” he said.
Sotorasib, the first FDA-approved KRAS G12C inhibitor, works by targeting and blocking the mutated KRAS protein, which drives tumor growth. Panitumumab, a monoclonal antibody, inhibits the epidermal growth factor receptor (EGFR), a protein overexpressed in many cancers, including colorectal cancer. Together, these drugs create a synergistic effect, enhancing treatment efficacy.
While the current study focused on later-line therapy, follow-up research is exploring the combination’s potential as a first-line treatment. Common side effects included diarrhea, fatigue, and nausea, but these were manageable.
This innovative therapy represents a significant advancement for patients with KRAS G12C metastatic colorectal cancer, providing a new lifeline where options were previously limited. As further studies unfold, the combination of sotorasib and panitumumab could redefine treatment protocols for this aggressive cancer.
Add comment